Using adeno-associated virus gene therapy to treat rare kidney disease
Lead Participant:
FREELINE THERAPEUTICS LIMITED
Abstract
Freeline is requesting a change of scope to project number 104902 – “Using AAV gene therapy to treat rare kidney disease” that would redistribute funds to enable critical safety risk mitigation experiments to be performed within the timelines of the grant.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| FREELINE THERAPEUTICS LIMITED | £1,564,444 | £ 938,666 |
Participant |
||
| INNOVATE UK |
People |
ORCID iD |
| Cathy Miles (Project Manager) |